Investors are cautioned that statements in this press release which are not strictly historical statements including, without limitation, express or implied statements or guidance regarding the expected results of the acquisition of Agena on Mesa’s future financial performance, including the accretive nature and the timing of the accretive nature of the acquisition, expected synergies following the acquisition of Agena, customer adoption of Agena’s products, the expected expansion of Mesa’s product lines, the timing of the closing of the acquisition and other statements identified by words like “believe,” “expect,” “may,” “will,” “should,” “seek,” or “could” and similar expressions, constitute forward-looking statements. ![]() This press release contains forward-looking statements within the meaning of the federal securities laws. We are unable to provide a reconciliation of forward-looking AOI because components of the calculation are inherently unpredictable and currently unknown. In this release, we refer to the non-GAAP financial measure adjusted operating income (“AOI”), which is defined to exclude the non-cash impact of amortization of intangible assets, stock-based compensation expense, and impairment loss on goodwill and long-lived assets. Mesa offers products and services to help our customers ensure product integrity, increase patient and worker safety, and improve the quality of life throughout the world. Mesa is a global leader in the design and manufacturing of critical quality control solutions for the pharmaceutical, healthcare and medical device industries. The COVID-19 revenues are expected to decrease significantly after that time.įor more information, visit the Mesa Acquisition of Agena presentation in the Investor Relations section of Mesa’s website at. Additionally, Agena is expected to deliver an additional $3 million to $5 million of COVID-19 related revenues during the first year of ownership at approximately the same gross profit percentages stated above. Additionally, excluding the impact of COVID-19 related revenues, purchase accounting and integration expenses, we expect adjusted operating income 1 as a percentage of revenues to approach 20% for the same first 12 months of ownership. Agena will operate as a distinct operating segment under Mesa and its results will be reported as part of a newly-created reportable segment, Clinical Genomics.Įxcluding the impact of COVID-19 related revenues, Agena is expected to add between $63 million to $67 million of revenues during the first 12 months of ownership (of which approximately 65% is expected to be recurring in nature), deliver high single digit organic revenues growth over the next several years and excluding the impact of purchase accounting, generate gross profit percentages in the mid to high 60’s. ![]() Mesa establishes a presence in San Diego, where Agena’s headquarters and facility will continue to be maintained, as well as strengthening Agena’s other global offices and brands. With this acquisition, we expect that over 90% of future revenues will be generated from sales to biopharma, medical device, and healthcare service verticals,” said Gary Owens, President and Chief Executive Officer of Mesa. ![]() “The acquisition of Agena is another critical step in redirecting the strategic trajectory of Mesa toward higher growth applications within the regulated segments of the life sciences tools market. Together, Mesa and Agena will join to pursue the common purpose of Protecting the Vulnerable®.Īgena is a leading clinical genomics tools company that develops, manufactures, and supplies highly sensitive, low-cost, high-throughput, genetic analysis solutions to clinical labs and development partners globally. ![]() With this highly strategic acquisition, Agena’s innovative approach to molecular diagnostics is now paired with Mesa’s proven approach to continuous improvement and operational and commercial efficiency. (NASDAQ:MLAB) today announced that it has completed the previously announced acquisition of Agena Biosciences, Inc. 20, 2021 (GLOBE NEWSWIRE) - Mesa Laboratories, Inc.
0 Comments
Leave a Reply. |